Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$98.70 USD

98.70
2,024,038

+1.59 (1.64%)

Updated May 16, 2024 03:59 PM ET

After-Market: $98.72 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.

AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment

by Zacks Equity Research

AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.

Abbott (ABT) Receives FDA's Approval for the TriClip TEER System

by Zacks Equity Research

Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.

Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval

by Zacks Equity Research

Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.

Henry Schein (HSIC) Buys TriMed to Expand in Orthopedic Space

by Zacks Equity Research

According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.

QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches

by Zacks Equity Research

QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.

Why Cardinal (CAH) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GE HealthCare's (GEHC) New Launch to Enhance Cardiac Care

by Zacks Equity Research

GE HealthCare's (GEHC) latest offering is likely to expand access to cardiac care by enabling more medical professionals to be able to capture cardiac images.

Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS

by Zacks Equity Research

Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.

Reasons to Add Cardinal Health (CAH) to Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now

by Zacks Equity Research

Ecolab's (ECL) focus on research and development raises optimism about the stock.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Globus Medical (GMED) Gains From New Launches Amid Macro Issues

by Zacks Equity Research

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Align (ALGN) Debuts Invisalign Palatal Expander in New Markets

by Zacks Equity Research

Align's (ALGN) Invisalign Palatal Expander system is now available in Australia and New Zealand for skeletal and dental expansion in growing patients.

Veeva Systems (VEEV) Makes Change to Front Office (revised)

by Zacks Equity Research

Veeva Systems' (VEEV) CFO Brent Bowman steps down, leading analysts to weigh in on the impact and prospects for the cloud-solutions company.

Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs

by Zacks Equity Research

Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.

QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing

by Zacks Equity Research

QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.

Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising

by Zacks Equity Research

Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.

Here's Why Investors Should Buy Alcon (ALC) Stock Right Now

by Zacks Equity Research

Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Veeva Systems' (VEEV) CFO Resignation Sparks 6% Stock Drop

by Zacks Equity Research

Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company.

Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy

by Zacks Equity Research

Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.

Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

by Zacks Equity Research

Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.